Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Eli Lilly and Company
Genmab
Hoffmann-La Roche
Revolution Medicines, Inc.
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Amgen
City of Hope Medical Center
Merck Sharp & Dohme LLC
Nuvalent Inc.
BioNTech SE
ArriVent BioPharma, Inc.
Merck Sharp & Dohme LLC
Roswell Park Cancer Institute
Taiho Oncology, Inc.
EMD Serono
Ottawa Hospital Research Institute
Pfizer
Hoffmann-La Roche
NRG Oncology
NRG Oncology
NRG Oncology
University Hospital, Brest
M.D. Anderson Cancer Center
Avistone Biotechnology Co., Ltd.
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
Qilu Pharmaceutical Co., Ltd.
Novartis
Guangzhou JOYO Pharma Co., Ltd
Sanofi
Qilu Pharmaceutical Co., Ltd.
Trans Tasman Radiation Oncology Group
University Hospital, Limoges
Abramson Cancer Center at Penn Medicine
Formycon AG
Wake Forest University Health Sciences
NRG Oncology
Prestige Biopharma Limited
Sun Yat-sen University